{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:43:20Z","timestamp":1780123400495,"version":"3.54.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gram-negative bacteria possess intrinsic resistance to glycopeptide antibiotics so these important antibacterial medications are only suitable for the treatment of Gram-positive bacterial infections. At the same time, polymyxins are peptide antibiotics, structurally related to glycopeptides, with remarkable activity against Gram-negative bacteria. With the aim of breaking the intrinsic resistance of Gram-negative bacteria against glycopeptides, a polycationic vancomycin aglycone derivative carrying an <jats:italic>n<\/jats:italic>-decanoyl side chain and five aminoethyl groups, which resembles the structure of polymyxins, was prepared. Although the compound by itself was not active against the Gram-negative bacteria tested, it synergized with teicoplanin against <jats:italic>Escherichia coli, Pseudomonas aeruginosa<\/jats:italic> and <jats:italic>Acinetobacter baumannii<\/jats:italic>, and it was able to potentiate vancomycin against these Gram-negative strains. Moreover, it proved to be active against vancomycin- and teicoplanin-resistant Gram-positive bacteria.<\/jats:p>","DOI":"10.1038\/s41598-022-24807-0","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:48:34Z","timestamp":1670082514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Synthesis of an amphiphilic vancomycin aglycone derivative inspired by polymyxins: overcoming glycopeptide resistance in Gram-positive and Gram-negative bacteria in synergy with teicoplanin in vitro"],"prefix":"10.1038","volume":"12","author":[{"given":"Zsolt","family":"Sz\u0171cs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Bereczki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Fenyvesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1l","family":"Herczegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Ostorh\u00e1zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-4547","authenticated-orcid":false,"given":"Anik\u00f3","family":"Borb\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"24807_CR1","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1002\/(SICI)1521-3773(19990802)38:15<2096::AID-ANIE2096>3.0.CO;2-F","volume":"38","author":"KC Nicolaou","year":"1999","unstructured":"Nicolaou, K. C., Boddy, C. N. C., Brase, S. & Winssinger, N. Chemistry, biology, and medicine of the glycopeptide antibiotics. Angew. Chem.-Int. Ed. 38, 2096\u20132152 (1999).","journal-title":"Angew. Chem.-Int. Ed."},{"issue":"9","key":"24807_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/ja.2014.111","volume":"67","author":"MS Butler","year":"2014","unstructured":"Butler, M. S., Hansford, K. A., Blaskovich, M. A., Halai, R. & Cooper, M. A. Glycopeptide antibiotics: back to the future. J. Antibiot. 67(9), 631\u2013644 (2014).","journal-title":"J. Antibiot."},{"key":"24807_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald, L. C. et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 66, e1\u2013e48 (2018).","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"24807_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/cid\/ciz871","volume":"71","author":"VW Stevens","year":"2020","unstructured":"Stevens, V. W. et al. Use of oral vancomycin for Clostridioides difficile infection and the risk of vancomycin-resistant enterococci. Clin. Infect. Dis. 71(3), 645\u2013651 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"24807_CR5","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026989","volume":"6","author":"D Zeng","year":"2016","unstructured":"Zeng, D. et al. Approved glycopeptide antibacterial drugs: Mechanism of action and resistance. Cold Spring Harb. Perspect. Med. 6, a026989 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"24807_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/B978-0-444-63749-9.00008-6","volume":"50","author":"S Biondi","year":"2016","unstructured":"Biondi, S., Chugunova, E. & Panunzio, M. From Natural products to drugs: Glyco- and lipoglycopeptides, a new generation of potent cell wall biosynthesis inhibitors. Stud. Nat. Prod. Chem. 50, 249\u2013297 (2016).","journal-title":"Stud. Nat. Prod. Chem."},{"issue":"31","key":"24807_CR7","doi-asserted-by":"publisher","first-page":"9314","DOI":"10.1021\/ja035901x","volume":"125","author":"CC McComas","year":"2003","unstructured":"McComas, C. C., Crowley, B. M. & Boger, D. L. Partitioning the loss in vancomycin binding affinity for D-Ala-D-Lac into lost H-bond and repulsive lone pair contributions. J. Am. Chem. Soc. 125(31), 9314\u20139315 (2003).","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"24807_CR8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1039\/C6MD00585C","volume":"8","author":"P Sarkar","year":"2017","unstructured":"Sarkar, P., Yarlagadda, V., Ghosh, C. & Haldar, J. A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics. Med. Chem. Comm. 8(3), 516\u2013533 (2017).","journal-title":"Med. Chem. Comm."},{"key":"24807_CR9","unstructured":"CDC\u2019s antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention, 2019, Atlanta, GA."},{"issue":"7643","key":"24807_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nature.2017.21550","volume":"543","author":"C Willyard","year":"2017","unstructured":"Willyard, C. The drug-resistant bacteria that pose the greatest health threats. Nature 543(7643), 15\u201315. https:\/\/doi.org\/10.1038\/nature.2017.21550 (2017).","journal-title":"Nature"},{"issue":"4","key":"24807_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.diagmicrobio.2019.01.020","volume":"94","author":"AM Peri","year":"2019","unstructured":"Peri, A. M. et al. Antimicrobial treatment challenges in the era of carbapenem resistance. Diagn. Microbiol. Infect. Dis. 94(4), 413\u2013425 (2019).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"1","key":"24807_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acsinfecdis.1c00367","volume":"8","author":"Y Acharya","year":"2022","unstructured":"Acharya, Y., Bhattacharyya, S., Dhanda, G. & Haldar, J. Emerging roles of glycopeptide antibiotics: Moving beyond gram-positive bacteria. ACS Infect. Dis. 8(1), 1\u201328 (2022).","journal-title":"ACS Infect. Dis."},{"issue":"5","key":"24807_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1021\/acsinfecdis.7b00258","volume":"4","author":"MAT Blaskovich","year":"2018","unstructured":"Blaskovich, M. A. T. et al. Developments in glycopeptide antibiotics. ACS Infect. Dis. 4(5), 715\u2013735 (2018).","journal-title":"ACS Infect. Dis."},{"issue":"7","key":"24807_CR14","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1021\/acs.jmedchem.8b01093","volume":"62","author":"G Dhanda","year":"2019","unstructured":"Dhanda, G., Sarkar, P., Samaddar, S. & Haldar, J. Battle against vancomycin-resistant bacteria: Recent developments in chemical strategies. J. Med. Chem. 62(7), 3184\u20133205 (2019).","journal-title":"J. Med. Chem."},{"key":"24807_CR15","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1021\/jm00100a010","volume":"35","author":"A Malabarba","year":"1992","unstructured":"Malabarba, A. et al. Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines. J. Med. Chem. 35, 4054\u20134060 (1992).","journal-title":"J. Med. Chem."},{"issue":"11","key":"24807_CR16","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1021\/jm500270w","volume":"57","author":"V Yarlagadda","year":"2014","unstructured":"Yarlagadda, V., Akkapeddi, P., Manjunath, G. B. & Haldar, J. Membrane active vancomycin analogues: A strategy to combat bacterial resistance. J. Med. Chem. 57(11), 4558\u20134568 (2014).","journal-title":"J. Med. Chem."},{"issue":"2","key":"24807_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1021\/acsinfecdis.5b00114","volume":"2","author":"V Yarlagadda","year":"2016","unstructured":"Yarlagadda, V. et al. Glycopeptide antibiotic to overcome the intrinsic resistance of gram-negative bacteria. ACS Infect. Dis. 2(2), 132\u2013139 (2016).","journal-title":"ACS Infect. Dis."},{"issue":"9","key":"24807_CR18","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1021\/acschembio.9b00565","volume":"14","author":"A Antonoplis","year":"2019","unstructured":"Antonoplis, A., Zang, X., Wegner, T., Wender, P. A. & Cegelski, L. Vancomycin-arginine conjugate inhibits growth of carbapenem-resistant E. coli and targets cell-wall synthesis. ACS Chem. Biol. 14(9), 2065\u20132070 (2019).","journal-title":"ACS Chem. Biol."},{"issue":"4","key":"24807_CR19","doi-asserted-by":"publisher","first-page":"E02416","DOI":"10.1128\/AAC.02416-20","volume":"65","author":"LF Neville","year":"2021","unstructured":"Neville, L. F. et al. In vivo targeting of Escherichia coli with vancomycin-arginine. Antimicrob. Agents Chemother. 65(4), E02416\u2013E02420 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24807_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.128122","volume":"45","author":"W Shi","year":"2021","unstructured":"Shi, W. et al. Design, synthesis, and antibacterial evaluation of vancomycin-LPS binding peptide conjugates. Bioorg. Med. Chem. Lett. 45, 128122 (2021).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"24807_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/med.21321","volume":"36","author":"SA Cochrane","year":"2014","unstructured":"Cochrane, S. A. & Vederas, J. C. Lipopeptides from bacillus and paenibacillus spp.: A gold mine of antibiotic candidates. Med. Res. Rev. 36, 4\u201331 (2014).","journal-title":"Med. Res. Rev."},{"key":"24807_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2217\/fmb.13.39","volume":"8","author":"T Velkov","year":"2013","unstructured":"Velkov, T., Roberts, K. D., Nation, R. L., Thompson, P. E. & Li, J. Pharmacology of polymyxins: New insights into an \u201cold\u201d class of antibiotics. Future Microbiol. 8, 711\u2013724 (2013).","journal-title":"Future Microbiol."},{"issue":"5","key":"24807_CR23","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1021\/jm900999h","volume":"53","author":"T Velkov","year":"2010","unstructured":"Velkov, T., Thompson, P. E., Nation, R. L. & Li, J. Structure\u2013activity relationships of polymyxin antibiotics. J. Med. Chem. 53(5), 1898\u20131916 (2010).","journal-title":"J. Med. Chem."},{"key":"24807_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4155\/fmc-2016-0011","volume":"8","author":"M Blanchet","year":"2016","unstructured":"Blanchet, M., Borselli, D. & Brunel, J. M. Polyamine derivatives: A revival of an old neglected scaffold to fight resistant Gram-negative bacteria?. Future Med. Chem. 8, 963\u2013973 (2016).","journal-title":"Future Med. Chem."},{"key":"24807_CR25","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1007\/s00253-020-10525-y","volume":"104","author":"J Yin","year":"2020","unstructured":"Yin, J. et al. Mechanisms of bactericidal action and resistance of polymyxins for Gram-positive bacteria. Appl. Microbiol. Biotechnol. 104, 3771\u20133780 (2020).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"24807_CR26","first-page":"3385","volume":"73","author":"H Rudilla","year":"2018","unstructured":"Rudilla, H. et al. (2018) Novel synthetic polymyxins kill Gram-positive bacteria. J. Antimicrob. Chemother. 73, 3385\u20133390 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"24807_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41429-020-0313-6","volume":"73","author":"Z Sz\u0171cs","year":"2020","unstructured":"Sz\u0171cs, Z. et al. N-Terminal guanidine derivatives of teicoplanin antibiotics strongly active against glycopeptide resistant Enterococcus faecium. J. Antibiotics 73, 603\u2013614 (2020).","journal-title":"J. Antibiotics"},{"key":"24807_CR28","doi-asserted-by":"crossref","unstructured":"Bereczki, I., Vimberg, V., L\u0151rincz, E., Papp, H., Nagy, L., K\u00e9ki, S., Batta, G., Mitrovi\u0107, A., Kos, J., Zsigmond, \u00c1., Hajd\u00fa, I., L\u0151rincz, Z., Bajusz, D., Petri, L., Hodek, J., F., Keser\u0171, G. M., Weber, J., Naesens, L., Herczegh, P., & Borb\u00e1s, A. Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria, Sci Rep. 12, 16001 (2022).","DOI":"10.1038\/s41598-022-20182-y"},{"key":"24807_CR29","doi-asserted-by":"crossref","unstructured":"Booth, P. M., Stone, D. J. M., & Williams, D. H. The Edman degradation of vancomycin: Preparation of vancomycin hexapeptide. J. Chem. Soc. Chem. Commun. 1694\u20131695 (1987).","DOI":"10.1039\/c39870001694"},{"issue":"7","key":"24807_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/ph13070139","volume":"13","author":"Z Sz\u0171cs","year":"2020","unstructured":"Sz\u0171cs, Z. et al. Reprogramming of the antibacterial drug vancomycin results in potent antiviral agents devoid of antibacterial activity. Pharmaceuticals 13(7), 139 (2020).","journal-title":"Pharmaceuticals"},{"key":"24807_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1021\/mp200505k","volume":"9","author":"Y Kam","year":"2012","unstructured":"Kam, Y., Rubinstein, A., Nissan, A., Halle, D. & Yavin, E. Detection of endogenous K-ras mRNA in living cells at a single base resolution by a PNA molecular beacon. Mol. Pharmaceut. 9, 685\u2013693 (2012).","journal-title":"Mol. Pharmaceut."},{"key":"24807_CR32","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1021\/ol500210z","volume":"16","author":"MU Luescher","year":"2014","unstructured":"Luescher, M. U., Vo, C. V. & Bode, J. W. SnAP reagents for the synthesis of piperazines and morpholines. Org. Lett. 16, 1236\u20131239 (2014).","journal-title":"Org. Lett."},{"key":"24807_CR33","doi-asserted-by":"crossref","unstructured":"Crane, C. M., Pierce, J. G., Leung, S. S. F., Tirado-Rives, J., Jorgensen, W. L., & Boger. D. L. Synthesis and evaluation of selected key methyl ether derivatives of vancomycin aglycon. J. Med. Chem. 53, 7229\u20137235 (2010).","DOI":"10.1021\/jm100946e"},{"issue":"5","key":"24807_CR34","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/jac\/dkr069","volume":"66","author":"DW Wareham","year":"2011","unstructured":"Wareham, D. W., Gordon, N. C. & Hornsey, M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 66(5), 1047\u20131051 (2011).","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"24807_CR35","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1128\/AAC.00922-10","volume":"54","author":"NC Gordon","year":"2010","unstructured":"Gordon, N. C., Png, K. & Wareham, D. W. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 54(12), 5316\u20135322 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"24807_CR36","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1128\/AAC.05870-11","volume":"56","author":"M Hornsey","year":"2012","unstructured":"Hornsey, M., Longshaw, C., Phee, L. & Wareham, D. W. In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob. Agents Chemother. 56(6), 3080\u20133085 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"24807_CR37","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1021\/acsinfecdis.1c00318","volume":"7","author":"E van Groesen","year":"2021","unstructured":"van Groesen, E. et al. Vancomyxins: Vancomycin-polymyxin nonapeptide conjugates that retain anti-Gram-positive activity with enhanced potency against Gram-negative strains. ACS Infect. Dis. 7(9), 2746\u20132754 (2021).","journal-title":"ACS Infect. Dis."},{"key":"24807_CR38","doi-asserted-by":"publisher","first-page":"8823","DOI":"10.1002\/anie.202002727","volume":"59","author":"F Umst\u00e4tter","year":"2020","unstructured":"Umst\u00e4tter, F. et al. Vancomycin resistance is overcome by conjugation of polycationic peptides. Angew. Chem. Int. Ed. 59, 8823\u20138827 (2020).","journal-title":"Angew. Chem. Int. Ed."},{"key":"24807_CR39","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/ja.2017.2","volume":"70","author":"Z Sz\u0171cs","year":"2017","unstructured":"Sz\u0171cs, Z. et al. Lipophilic teicoplanin pseudoaglycon derivatives are active against vancomycin- and teicoplanin-resistant enterococci. J. Antibiot. 70, 664\u2013670 (2017).","journal-title":"J. Antibiot."},{"key":"24807_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000069774","volume":"49","author":"F Fernandez-Cuenca","year":"2003","unstructured":"Fernandez-Cuenca, F., Martinez-Martinez, L., Pascual, A. & Perea, E. J. In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinobacter baumannii. Chemotherapy 49, 24\u201326 (2003).","journal-title":"Chemotherapy"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24807-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24807-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24807-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T14:09:45Z","timestamp":1670422185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24807-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["24807"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-24807-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20921"}}